ArticleJournal of the American Chemical Society2009
Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-beta deposits.
Article in Journal of the American Chemical Society, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed.
- Recent Advances in Organofluoroprobes for Brain Imaging: Progress, Challenges, and Future Directions.ACS pharmacology & translational science · 2026Review
- 1,3,2-Dioxaborine-based mero-polyanionic dyes: high-extinction NIR-absorbing polymethines.RSC advances · 2026Article
- Dexter Energy Transfer Photocatalytic Microdissection of Amyloid Plaques in Alzheimer's Disease.JACS Au · 2026Article
- High-affinity nitrogen-doped graphene quantum dots for selectiveRSC advances · 2026Article
- Design and Evaluation of Quinoline-derived Fluorophores for Labeling Amyloid Beta 1-42 in Alzheimer's Disease.ACS omega · 2026Article
- AI-Driven Acceleration of Fluorescence Probe Discovery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Discovery of NIRF theranostic probes targeting amyloid-β and cholinesterases in Alzheimer's disease models.Nature communications · 2026Article
- Highly sensitive chemiluminescence imaging of misfolded proteins in neurodegenerative models.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Curcumin as theranostics: imaging-guided therapeutics in oncology and neurodegenerative diseases.Frontiers in nutrition · 2026Review
- Host-Gated Enzymatic Release (H-GER) Enables Colorimetric Transduction for Enzyme Measurement.ACS applied materials & interfaces · 2025Article
- Response of Fluorescent Boron Difluoride β-Diketonates to X-Rays.Journal of fluorescence · 2025Article
- Ligands for Protein Fibrils of Amyloid-β, α-Synuclein, and Tau.Chemical reviews · 2025Review
- N-Alkylamino Stilbene Compounds as Amyloid β Inhibitors for Alzheimer's Disease Research.Molecules (Basel, Switzerland) · 2025Article
- Bioimaging and Sensing Properties of Curcumin and Derivatives.International journal of molecular sciences · 2025Review
- Super-Resolution Mapping and Quantification of Molecular Diffusion via Single-Molecule Displacement/Diffusivity Mapping (SMAccounts of chemical research · 2025Article
- Systematic review of curcumin-based optical imaging for amyloid-β detection in Alzheimer's disease models.Current journal of neurology · 2025Review
- Regulating Triplet Excitons of Organic Luminophores for Promoted Bioimaging.Current medicinal chemistry · 2025Review
- Half-Curcumin-Based Chemiluminescence Probes and Their Applications in Detecting Quasi-Stable Oxidized Proteins.Angewandte Chemie (International ed. in English) · 2024Article
- Cationic Curcumin Nanocrystals Liposomes for Improved Oral Bioavailability: Formulation Development, Optimization, In Vitro and In Vivo Evaluation.Pharmaceutics · 2024Article
- Nanoscale myelinogenesis image in developing brain via super-resolution nanoscopy by near-infrared emissive curcumin-BODIPY derivatives.Journal of nanobiotechnology · 2024Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Amyloid-beta (Abeta) deposits have been identified as key players in the progression of Alzheimer's disease (AD). Recent evidence indicates that the deposits probably precede and induce the neuronal atrophy. Therefore, methods that enable monitoring the pathology before clinical symptoms are observed would be beneficial for early AD detection. Here, we report the design, synthesis, and testing of a curcumin-derivatized near-infrared (NIR) probe, CRANAD-2. Upon interacting with Abeta aggregates, CRANAD-2 undergoes a range of changes, which include a 70-fold fluorescence intensity increase, a 90 nm blue shift (from 805 to 715 nm), and a large increase in quantum yield. Moreover, this probe also shows a high affinity for Abeta aggregates (K(d) = 38.0 nM), a reasonable log P value (log P = 3), considerable stability in serum, and a weak interaction with albumin. After intravenous injection of this probe, 19-month-old Tg2576 mice exhibited significantly higher relative signal than that of the control mice over the same period of time. In summary, CRANAD-2 meets all the requirements for a NIR contrast agent for the detection of Abeta plaques both in vitro and in vivo. Our data point toward the feasibility of monitoring the progress of the disease by NIR imaging with CRANAD-2. In addition, we believe that our probe could be potentially used as a tool for drug screening.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.